Cancer, AI, and Health Equity ++... ++... +...

Presented at ASH 2025: EPCORE CLL-1 trial on epcoritamab monotherapy for Richter transformation December 08, 2025 • The Lancet Group https://thelancethaematology.buzzsprout.com/1564352/episodes/18278085-presented-at-ash-2025-epcore-cll-1-trial-on-epcoritamab-monotherapy-for-richter-transformation?utm_campaign=infocusalerts-oncology&utm_medium=email&_hsenc=p2ANqtz-8sIcpt_0Rdx3AGClxNAhIPGTsAOtHI25vf2j-sIO0Az1efQqAlYvZXr_s3AJqJ_oslWx47gcP3bg4fZq_JIM1aYkoUCA&_hsmi=397839338&utm_content=397683959&utm_source=hs_email ASH | American Society of Hematology https://www.thelancet.com/events/conferences/american-society-haematology?dgcid=hubspot_email_infocusalerts-oncology_feature_ash25&utm_campaign=infocusalerts-oncology&utm_medium=email&_hsenc=p2ANqtz-9T06Ddtq8Hm21LDrJrqIjm2Hp4KJlr9GYZs4rlXToPh29kN1Tu6mVFfXenSNakAfQFMf3sDFBf4x164woxmyPinv5SVA&_hsmi=397839338&utm_content=397683959&utm_source=hs_email Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00605-9/fulltext?dgcid=hubspot_email_infocusalerts-oncology_feature&utm_campaign=infocusalerts-oncology&utm_medium=email&_hsenc=p2ANqtz-9eFlaZaARDfH8NC2jsFPGainS0zuU25Eiot83PcUie6F0ccplOrJ0TR2_v-6GzMAcM3WxM6UzVpdXEzFyGTk0aurUpOw&_hsmi=397839338&utm_content=397683959&utm_source=hs_email Cancer, AI, and Health Equity https://www.thelancet.com/series-do/cancer-ai-and-health-equity?dgcid=hubspot_email_infocusalerts-oncology_feature_landigaicancer25&utm_campaign=infocusalerts-oncology&utm_medium=email&_hsenc=p2ANqtz-_76n_cuXkJlRgQIIRcXAn1Tv7GeUbk7njd6YmM9qds5mc6T5BjM-3jh-5ZOItpToU_IfZsHC38uJP-RhyZVpuB21hQhA&_hsmi=397839338&utm_content=397683959&utm_source=hs_email Dec 2025 Volume 26Number 12p1511-1684, e620-e706 https://www.thelancet.com/journals/lanonc/issue/vol26no12/PIIS1470-2045(25)X0012-7